Access Group Thought Leadership

A Stagnating Industry One of the core realities of contraceptive research & development (R&D) is that many promising products never make it to market. Some stall in early development and others face barriers during clinical trials, regulatory review, or introduction. Developing a new or improved contraceptive is a risky, expensive, and time-consuming process, complicated by: Scientific and biological challenges : Human reproduction is complex and controlling a drug’s systemic

Guest Contributor | Kelly Dannucci, Sr. Manager, Global Access - Medicines360/Impact RH360 Harmonizing pharmaceutical product labeling...

This post has been adapted from another blog titled ‘Updated Couple Years of Protection: Literature Review and Guidance’. Original text...

Guest Contributors | Chastain Mann, EECO Project Director, WCG Cares & Ashley Jackson, EECO Project Deputy Director, PSI This post...

Guest Contributor | Written by Kendal Danna, PSI Technical Advisor, Reproductive Health This post originally appeared on PSI. View...

Written by Kate Rademacher, FHI 360 This post originally appeared on Medium. View the original post here Saturday is February 29 which...

Written by Ashley Jackson, PSI This post originally appeared on PSI. View the original post here . This April, Madagascar became the...

Written by Kate Rademacher, FHI 360 This post originally appeared in the K4Health Blog and is re-posted here with permission. Over the...